PTC Therapeutics (PTCT) calls active on FDA approval of Sarepta's (SRPT) eteplirsen
Tweet
Share
E-mailGet Alerts PTCT Hot Sheet
Up)Join SI Premium – FREE
PTC Therapeutics (NASDAQ: PTCT) whose Translarna drug seeks to treat nonsense mutation Duchenne muscular dystrophy is recently up 15%, after the FDA granted accelerated approval to Sarepta's (SRPT) eteplirsen, the company's treatment of Duchenne muscular dystrophy. PTCT October 11 and 12 calls are active on total call volume of 805 contracts (134 puts).
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- IMAC Holdings (BACK) halted on volatility, up 26%
- SL Green Realty (SLG) April 50 straddle into quarter results
- Prologis (PLD) April 115 straddle into quarter results
Create E-mail Alert Related Categories
Options, Trader TalkSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
